Healthcare technology firm Covidien has received approval from Health Canada for its generic technetium-99m sestamibi kit.
The myocardial perfusion imaging radiopharmaceutical can be substituted for the Cardiolite agent from Lantheus Medical Imaging of North Billerica, MA, according to Covidien of Dublin, Ireland. Covidien said it expects the kit will be available to Canadian customers this summer.
Related Reading
Covidien closes VNUS purchase, June 18, 2009
Covidien to acquire VNUS for $440M, May 8, 2009
Covidien adds to Q2 sales, May 1, 2009
Covidien, B&W to tackle medical isotope dilemma, January 28, 2009
Covidien to move HQ to Ireland, January 7, 2009
Copyright © 2009 AuntMinnie.com